Sofinnova Partners

Sofinnova Partners

Services financiers

Paris, Ile-de-France 29 817 abonnés

Sofinnova Partners is a leading European VC firm in life sciences, specializing in healthcare and sustainability.

À propos

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.8 billion under management. For more information, please visit: www.sofinnovapartners.com

Secteur
Services financiers
Taille de l’entreprise
11-50 employés
Siège social
Paris, Ile-de-France
Type
Partenariat
Fondée en
1972
Domaines
Pharmaceutical / biotech, Medical devices, Industrial Biotechnology, Sustainability, Biopharma, Medtech, Venture Capital, Private Equity, Biotech et Biotechnology

Lieux

Employés chez Sofinnova Partners

Nouvelles

  • Voir la page d’organisation pour Sofinnova Partners, visuel

    29 817  abonnés

    Victoria English from MedNous (Evernow Publishing Ltd) spoke with Paola Pozzi, Partner at Sofinnova Partners, about the Sofinnova Cell and Gene Therapy report. The report explores key industry trends shaping the future of advanced therapies, including: •  The expanding role of cell & gene therapies in venture capital and M&A •  The increasing importance of delivery technologies in advancing treatments •  A shift in investment focus toward clinical-stage biotech Read MedNous’ latest piece to learn more and stay tuned for the Sofinnova Cell and Gene Therapy report coming soon.

    Voir le profil de Victoria English, visuel

    MS at Columbia University - Graduate School of Journalism

    The February edition of MedNous is now out, featuring a review of new concepts for the development of Alzheimer's disease drugs. We also report on FDA approval of a non-opioid drug for pain. Next to this is a research article by the CEO of PharmNovo of Sweden describing an experimental opioid treatment for the same indication. Trends in investment for cell and gene therapies are detailed in a report by Sofinnova. Finally, do you want to understand more about the federated analysis of data? Then read Philip Quinlan's article about a new project between academia and industry in the UK. For a complimentary copy of this issue, please email editor@evernow.eu.

    • Aucune description alternative pour cette image
  • Today, we are focusing on Micropep Technologies, founded in 2016 with a mission to protect the future of global food production.   With 4.9m tons of chemical herbicide used every year globally and 40% of crops lost each year to pests, Micropep Technologies is leveraging micropeptides to develop the next generation of efficient and sustainable solutions for crop protection, helping agricultural systems adapt to the impact of climate change.

    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
  • Antoine Papiernik discussed with Shani Alexander why MedTech companies focusing on cardiovascular diseases, neurological conditions, women’s health, or robotic surgery will find European investors willing to back them: “The cardiovascular space remains pretty important and investment in devices to address women’s health is long overdue.” Read the full article to learn more—link in the comments.

    • Aucune description alternative pour cette image
  • Voir la page d’organisation pour Sofinnova Partners, visuel

    29 817  abonnés

    Today, we’re highlighting a Sofinnova Partners Industrial Biotech portfolio company that is working to transform our everyday meals with plant-based meats… 🌱🥩 NOVAMEAT, led by Giuseppe Scionti, is a sustainable food technology company combining advanced food science with culinary expertise to provide a sustainable protein source for the world’s growing population. Their tasty products, unique technology, in-house production, and competitive cost structure, give Novameat the potential to revolutionize the food industry by offering better plant-based alternatives to animal proteins - seizing the enormous market opportunity that exists in the food sector.

    • Aucune description alternative pour cette image
  • Today, we’re spotlighting a portfolio company that Michael Krel, Partner in Sofinnova’s Industrial Biotech strategy, invested in 2019: AFYREN   AFYREN, a sustainable chemicals company—meaning it produces safer, eco-friendly chemicals, to enable the manufacturing sector to work in a cleaner, low-carbon way that’s better for the environment.   AFYREN uses unique fermentation technology to replace petroleum-based ingredients in everyday products, like lotions, soaps, makeup, with plant-based alternatives, producing zero industrial waste.   We’re incredibly proud to support AFYREN and their stellar team and are excited to see the company continue to scale its impact.  

    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
  • Sofinnova Partners a republié ceci

    Voir le profil de Simon Turner, visuel

    Partner at Sofinnova Partners

    After the Radiology AI summit in London and WAIC in Cannes and LOTS of pitches, both formal and informal, I wanted to share a few thoughts on pitching ideas. Here are three simple things I try to do myself that hold true for any pitch (imho): 1. Know Your Audience Not everyone knows what you do, some people are specialists, others from a different walk of life. Ask a few open questions to help you know what their expertise level is. 2. Read the Room & Adapt If we’re in a formal pitch meeting, give me structure. If we’re chatting informally, keep it conversational. And if I look confused, don’t plow ahead—clarify, adjust, and make sure your main message lands. 3. K.I.S.S. (Keep It Simple, Stupid) The best pitches stick because they’re clear and compelling. I should be able to explain in one sentence what you do to anyone I meet. We can all improve on the art of communication. So, fellow investors and founders, what are your top pitching tips? Would love to hear from you. (Shout out to Dr. Franz MJ Pfister, MD, MBA, Dr. Julia Moosbauer, Sebastien Ourselin FREng FMedSci, Nicolas Huber and Victor Savevski for having me take part)

    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
  • Today, we’re highlighting Prometheus Materials, a Sofinnova Partners portfolio company helping to accelerate the transition to lower-carbon building materials by leveraging the power of nature.   Prometheus Materials is a brilliant example of the power of biology to replace existing industrial processes with climate-friendly alternatives. We’re proud to have been an early backer and we look forward to continuing to work with Loren Burnett and his team as they transform architecture and the construction industry. 

    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
  • Voir la page d’organisation pour Sofinnova Partners, visuel

    29 817  abonnés

    Sofinnova Partners is known for partnering with entrepreneurs who are solving the world’s most pressing problems across healthcare. However, our work around sustainability has been less in the spotlight. Join us as we delve into some of the incredible companies in our Industrial Biotech portfolio.   For more than 10 years, Sofinnova Industrial Biotech - led by Joško Bobanović, Mary McCarthy, Michael Krel and Guillaume Baxter - has invested in technologies that will make our food, agriculture, chemicals and materials industries more sustainable.   This work could not be more important so, starting this week, we will be putting the spotlight on Sofinnova Partners Industrial Biotech strategy and some of the incredible companies we have invested in over the years.   Stay tuned for more.

    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image
    • Aucune description alternative pour cette image

Pages similaires

Parcourir les offres d’emploi

Financement